<\/iframe> <\/p>\n Cada any, a Espanya es diagnostiquen m\u00e9s de 5.000 persones de limfoma no Hodgkin B, una xifra que el converteix en el c\u00e0ncer de sang m\u00e9s freq\u00fcent al nostre pa\u00eds. Afortunadament, m\u00e9s del 60 % dels pacients el supera. No obstant aix\u00f2, la resta recau i, en alguns casos, l\u2019afecci\u00f3 es torna resistent a les ter\u00e0pies disponibles.<\/p>\n Des del desenvolupament de les primeres c\u00e8l\u00b7lules CAR-T l\u2019any 1989, les recerques m\u00e9s innovadores a escala internacional han anat avan\u00e7ant el seu potencial en el tractament del c\u00e0ncer. Actualment, les ter\u00e0pies d\u2019immunoter\u00e0pia CAR s\u2019han erigit com les m\u00e9s disruptives en el cas de c\u00e0ncers de la sang fins ara sense tractament. De fet, molts investigadors les presenten com un canvi de paradigma: aquestes ter\u00e0pies ens estan donant solucions a reptes en el tractament del c\u00e0ncer que fins ara semblaven impossibles de resoldre.<\/p>\n En aquest context, \u201dla Caixa\u201d i l\u2019<a href=\"http:\/\/www.santpau.cat\/web\/public\/home\" rel=\"noopener noreferrer\" target=\"_blank\">Hospital de Sant Pau<\/a> enforteixen lligams per desenvolupar un assaig cl\u00ednic pioner a Espanya per a pacients de limfoma no Hodgkin B que han esgotat les opcions terap\u00e8utiques. Amb una aportaci\u00f3 de 2 milions d\u2019euros repartida en 4 anys, \u201dla Caixa\u201d far\u00e0 possible investigar l\u2019aplicaci\u00f3 d\u2019immunoter\u00e0pia CAR-T seleccionant els limf\u00f2cits T de mem\u00f2ria.<\/p>\n L\u2019acord de col\u00b7laboraci\u00f3 s\u2019ha presentat avui en una roda de premsa liderada per Jaume Gir\u00f3, director general de la Fundaci\u00f3 Banc\u00e0ria \u201dla Caixa\u201d, i Albert Salazar, director gerent de l\u2019Hospital de Sant Pau. El projecte est\u00e0 coordinat pels doctors Jordi Sierra, cap del <a href=\"http:\/\/www.santpau.cat\/ca\/web\/public\/hc-inici\" rel=\"noopener noreferrer\" target=\"_blank\">Servei d\u2019Hematologia<\/a> de l\u2019Hospital de Sant Pau, i Javier Briones, cap cl\u00ednic del mateix servei.<\/p>\n Atacar el c\u00e0ncer des de dins<\/strong><\/p>\n Els limf\u00f2cits T de mem\u00f2ria s\u00f3n els encarregats de detectar i eliminar les c\u00e8l\u00b7lules canceroses del nostre organisme gr\u00e0cies als anomenats receptors d\u2019ant\u00edgens <\/strong>situats a la seva superf\u00edcie cel\u00b7lular. No obstant aix\u00f2, el nombre de limf\u00f2cits T de mem\u00f2ria del nostre organisme \u00e9s molt baix i, a m\u00e9s, algunes c\u00e8l\u00b7lules canceroses tenen la capacitat d\u2019amagar-s\u2019hi al darrere i aconseguir que el tumor passi desapercebut i es continu\u00ef desenvolupant. \u00c9s el cas, per exemple, del limfoma no Hodgkin B, que s\u2019origina quan les c\u00e8l\u00b7lules conegudes com limf\u00f2cits B es reprodueixen de manera descontrolada i els limf\u00f2cits T no els aconsegueixen detectar.<\/p>\n <img decoding=\"async\" alt=\"Immunoter\u00e0pia CAR-T\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg\" style=\"width: 400px; height: 255px;\"\/><\/p>\n La immunoter\u00e0pia CAR T t\u00e9 per estrat\u00e8gia la millora dels limf\u00f2cits T per fer-los m\u00e9s forts i nombrosos. Els investigadors extreuen aquestes c\u00e8l\u00b7lules del propi pacient i les modifiquen gen\u00e8ticament per enriquir els seus receptors d\u2019ant\u00edgens. Aix\u00ed, els ara anomenats receptors d\u2019ant\u00edgens quim\u00e8rics <\/strong>\u2013abreujats com CAR, per les seves sigles en angl\u00e8s\u2013 s\u00f3n m\u00e9s eficients i precisos a l\u2019hora de localitzar les c\u00e8l\u00b7lules canceroses. Els limf\u00f2cits CAR T es multipliquen al laboratori i, una vegada reintrodu\u00efts a la sang del pacient, s\u00f3n capa\u00e7os de recon\u00e8ixer i, en molts casos, eliminar les c\u00e8l\u00b7lules del limfoma.<\/p>\n La clau de l\u2019\u00e8xit: els limf\u00f2cits T de mem\u00f2ria<\/strong><\/p>\n Un dels aspectes m\u00e9s innovadors de l\u2019assaig cl\u00ednic de l\u2019Hospital de Sant Pau \u00e9s l\u2019\u00fas exclusiu dels limf\u00f2cits T de mem\u00f2ria per desenvolupar la immunoter\u00e0pia. \u201cFins ara es feien servir tots els limf\u00f2cits T per aplicar la immunoter\u00e0pia CAR T\u201d, comenta Javier Briones, responsable cl\u00ednic del projecte. \u201cPer\u00f2 hi ha molts tipus de limf\u00f2cits T, cadascun amb una capacitat diferent per eliminar un tumor. Ara sabem que els limf\u00f2cits T de mem\u00f2ria s\u00f3n els que millor ho fan. Quan ho vam descobrir, de seguida ens vam preguntar: i si en lloc de fer servir totes les c\u00e8l\u00b7lules T com estem fent fins ara, intentem seleccionar les que siguin m\u00e9s eficients?\u201d.<\/p>\n \u201cAmb aquesta immunoter\u00e0pia CAR T aconseguim que el sistema immunitari del propi pacient o, en alguns casos d\u2019un donant sa, elimini les c\u00e8l\u00b7lules tumorals amb una pot\u00e8ncia 500.000 vegades millor, molt superior a qualsevol tractament aconseguit fins ara\u201d, conclou Jordi Serra.<\/p>\n Gr\u00e0cies a l\u2019acord de col\u00b7laboraci\u00f3 entre \u201dla Caixa\u201d i l\u2019Hospital de Sant Pau, enguany comen\u00e7ar\u00e0 la fase I de l\u2019assaig amb pacients amb limfoma no Hodgkin B refractaris als tractaments i s\u2019obrir\u00e0, aix\u00ed, una nova esperan\u00e7a contra el c\u00e0ncer limf\u00e0tic.<\/p>\n<\/p><\/div>\n<\/body><\/html><\/p>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<iframe loading=\"lazy\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\" frameborder=\"0\" height=\"225\" src=\"https:\/\/www.youtube.com\/embed\/vtQaIUeuy_c\" width=\"400\"><\/iframe> <\/p>\n Cada any, a Espanya es diagnostiquen m\u00e9s de 5.000 persones de limfoma no Hodgkin B, una xifra que el converteix en el c\u00e0ncer de sang m\u00e9s freq\u00fcent al nostre pa\u00eds. Afortunadament, m\u00e9s del 60 % dels pacients el supera. No obstant aix\u00f2, la resta recau i, en alguns casos, l\u2019afecci\u00f3 es torna resistent a les ter\u00e0pies disponibles.<\/p>\n Des del desenvolupament de les primeres c\u00e8l\u00b7lules CAR-T l\u2019any 1989, les recerques m\u00e9s innovadores a escala internacional han anat avan\u00e7ant el seu potencial en el tractament del c\u00e0ncer. Actualment, les ter\u00e0pies d\u2019immunoter\u00e0pia CAR s\u2019han erigit com les m\u00e9s disruptives en el cas de c\u00e0ncers de la sang fins ara sense tractament.<\/p>\n","protected":false},"author":1,"featured_media":3181,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[519],"tags":[356,501,502,397,398,365],"class_list":["post-2021","post","type-post","status-publish","format-standard","hentry","category-investigacio","tag-assajos-clinics","tag-cancer-ca","tag-hospital-de-sant-pau-ca","tag-immunoterapia","tag-limfocits","tag-recerca"],"acf":[],"yoast_head":"\n<title>Un assaig pioner contra el c\u00e0ncer limf\u00e0tic amb limf\u00f2cits T de mem\u00f2ria - Blog CaixaCi\u00e8ncia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un assaig pioner contra el c\u00e0ncer limf\u00e0tic amb limf\u00f2cits T de mem\u00f2ria - Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"og:description\" content=\"Cada any, a Espanya es diagnostiquen m\u00e9s de 5.000 persones de limfoma no Hodgkin B, una xifra que el converteix en el c\u00e0ncer de sang m\u00e9s freq\u00fcent al nostre pa\u00eds. Afortunadament, m\u00e9s del 60 % dels pacients el supera. No obstant aix\u00f2, la resta recau i, en alguns casos, l\u2019afecci\u00f3 es torna resistent a les ter\u00e0pies disponibles. Des del desenvolupament de les primeres c\u00e8l\u00b7lules CAR-T l\u2019any 1989, les recerques m\u00e9s innovadores a escala internacional han anat avan\u00e7ant el seu potencial en el tractament del c\u00e0ncer. Actualment, les ter\u00e0pies d\u2019immunoter\u00e0pia CAR s\u2019han erigit com les m\u00e9s disruptives en el cas de c\u00e0ncers de la sang fins ara sense tractament.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-10T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-05T08:31:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1631\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"La Caixa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"La Caixa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/\",\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/\",\"name\":\"Un assaig pioner contra el c\u00e0ncer limf\u00e0tic amb limf\u00f2cits T de mem\u00f2ria - Blog CaixaCi\u00e8ncia\",\"isPartOf\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg\",\"datePublished\":\"2019-05-10T00:00:00+00:00\",\"dateModified\":\"2020-05-05T08:31:09+00:00\",\"author\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/#primaryimage\",\"url\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg\",\"contentUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg\",\"width\":2560,\"height\":1631},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\",\"url\":\"https:\/\/blog.caixaresearch.org\/\",\"name\":\"Blog CaixaCi\u00e8ncia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.caixaresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a\",\"name\":\"La Caixa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g\",\"caption\":\"La Caixa\"},\"sameAs\":[\"https:\/\/blog.caixaresearch.org\"],\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/author\/caixaciencialamagnetica-net\/\"}]}<\/script>\n","yoast_head_json":{"title":"Un assaig pioner contra el c\u00e0ncer limf\u00e0tic amb limf\u00f2cits T de mem\u00f2ria - Blog CaixaCi\u00e8ncia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/","og_locale":"ca_ES","og_type":"article","og_title":"Un assaig pioner contra el c\u00e0ncer limf\u00e0tic amb limf\u00f2cits T de mem\u00f2ria - Blog CaixaCi\u00e8ncia","og_description":"Cada any, a Espanya es diagnostiquen m\u00e9s de 5.000 persones de limfoma no Hodgkin B, una xifra que el converteix en el c\u00e0ncer de sang m\u00e9s freq\u00fcent al nostre pa\u00eds. Afortunadament, m\u00e9s del 60 % dels pacients el supera. No obstant aix\u00f2, la resta recau i, en alguns casos, l\u2019afecci\u00f3 es torna resistent a les ter\u00e0pies disponibles. Des del desenvolupament de les primeres c\u00e8l\u00b7lules CAR-T l\u2019any 1989, les recerques m\u00e9s innovadores a escala internacional han anat avan\u00e7ant el seu potencial en el tractament del c\u00e0ncer. Actualment, les ter\u00e0pies d\u2019immunoter\u00e0pia CAR s\u2019han erigit com les m\u00e9s disruptives en el cas de c\u00e0ncers de la sang fins ara sense tractament.","og_url":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/","og_site_name":"Blog CaixaCi\u00e8ncia","article_published_time":"2019-05-10T00:00:00+00:00","article_modified_time":"2020-05-05T08:31:09+00:00","og_image":[{"width":2560,"height":1631,"url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg","type":"image\/jpeg"}],"author":"La Caixa","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"La Caixa","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/","url":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/","name":"Un assaig pioner contra el c\u00e0ncer limf\u00e0tic amb limf\u00f2cits T de mem\u00f2ria - Blog CaixaCi\u00e8ncia","isPartOf":{"@id":"https:\/\/blog.caixaresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/#primaryimage"},"image":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg","datePublished":"2019-05-10T00:00:00+00:00","dateModified":"2020-05-05T08:31:09+00:00","author":{"@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/ca\/un-assaig-pioner-contra-el-cancer-limfatic-amb-limfocits-t-de-memoria\/#primaryimage","url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg","contentUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ImmunoterC3A0piaCAR-TCAT-laCaixa.jpg","width":2560,"height":1631},{"@type":"WebSite","@id":"https:\/\/blog.caixaresearch.org\/#website","url":"https:\/\/blog.caixaresearch.org\/","name":"Blog CaixaCi\u00e8ncia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.caixaresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a","name":"La Caixa","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g","caption":"La Caixa"},"sameAs":["https:\/\/blog.caixaresearch.org"],"url":"https:\/\/blog.caixaresearch.org\/ca\/author\/caixaciencialamagnetica-net\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/2021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/comments?post=2021"}],"version-history":[{"count":3,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/2021\/revisions"}],"predecessor-version":[{"id":3476,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/2021\/revisions\/3476"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media\/3181"}],"wp:attachment":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media?parent=2021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/categories?post=2021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/tags?post=2021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}